» Articles » PMID: 38328306

Exploring the Tumor Micro-environment in Primary and Metastatic Tumors of Different Ovarian Cancer Histotypes

Overview
Specialty Cell Biology
Date 2024 Feb 8
PMID 38328306
Authors
Affiliations
Soon will be listed here.
Abstract

Ovarian cancer is a highly heterogeneous disease consisting of at least five different histological subtypes with varying clinical features, cells of origin, molecular composition, risk factors, and treatments. While most single-cell studies have focused on High grade serous ovarian cancer, a comprehensive landscape of the constituent cell types and their interactions within the tumor microenvironment are yet to be established in the different ovarian cancer histotypes. Further characterization of tumor progression, metastasis, and various histotypes are also needed to connect molecular signatures to pathological grading for personalized diagnosis and tailored treatment. In this study, we leveraged high-resolution single-cell RNA sequencing technology to elucidate the cellular compositions on 21 solid tumor samples collected from 12 patients with six ovarian cancer histotypes and both primary (ovaries) and metastatic (omentum, rectum) sites. The diverse collection allowed us to deconstruct the histotypes and tumor site-specific expression patterns of cells in the tumor, and identify key marker genes and ligand-receptor pairs that are active in the ovarian tumor microenvironment. Our findings can be used in improving precision disease stratification and optimizing treatment options.

Citing Articles

Identification biomarkers and therapeutic targets of disulfidptosis-related in rheumatoid arthritis via bioinformatics, molecular dynamics simulation, and experimental validation.

Xu B, Zhang H, Shen B, Wu J, Shi M, Li X Sci Rep. 2025; 15(1):8779.

PMID: 40082645 PMC: 11906621. DOI: 10.1038/s41598-025-93656-4.

References
1.
Kan T, Zhang S, Zhou S, Zhang Y, Zhao Y, Gao Y . Single-cell RNA-seq recognized the initiator of epithelial ovarian cancer recurrence. Oncogene. 2022; 41(6):895-906. DOI: 10.1038/s41388-021-02139-z. View

2.
Scurr L, Guminski A, Chiew Y, Balleine R, Sharma R, Lei Y . Ankyrin repeat domain 1, ANKRD1, a novel determinant of cisplatin sensitivity expressed in ovarian cancer. Clin Cancer Res. 2008; 14(21):6924-32. DOI: 10.1158/1078-0432.CCR-07-5189. View

3.
Castellano G, Reid J, Alberti P, Carcangiu M, Tomassetti A, Canevari S . New potential ligand-receptor signaling loops in ovarian cancer identified in multiple gene expression studies. Cancer Res. 2006; 66(22):10709-19. DOI: 10.1158/0008-5472.CAN-06-1327. View

4.
Li W, Ma H, Zhang J, Zhu L, Wang C, Yang Y . Unraveling the roles of CD44/CD24 and ALDH1 as cancer stem cell markers in tumorigenesis and metastasis. Sci Rep. 2017; 7(1):13856. PMC: 5653849. DOI: 10.1038/s41598-017-14364-2. View

5.
Zhou X, Hu W, Qin X . The role of complement in the mechanism of action of rituximab for B-cell lymphoma: implications for therapy. Oncologist. 2008; 13(9):954-66. DOI: 10.1634/theoncologist.2008-0089. View